Apart from tumour, treatment and patient characteristics at diagnosis, access to healthcare delivery may as well play a significant role in breast cancer prognosis. This study aimed to assess the additional impact exerted on survival by travel burden—a surrogate indicator of limited access to healthcare- expressed as geographical distance and/or time needed to reach the tertiary healthcare center from the patient’s residence. Between 1997 and 2005, 2,789 women participated in therapeutic clinical trials conducted by the Hellenic Cooperative Oncology Group. The effect of geographical distance and travel time between patient’s residence and treating hospital on survival was estimated using Cox proportional hazards regression adjusting for age, menopausal status, tumour size/grade, positive nodes (number), hormonal receptor status, HER2 overexpression, surgery type/treatment protocol as well as for body mass index >30 kg/m2. More aggressive tumour features, older treatment protocols and modifiable patient characteristics, such as obesity (HR: 1.27) adversely impacted on breast cancer survival. In addition, less studied indicators of access to healthcare, such as geographic distance >350 km and travel time >4 h were independently and significantly associated with worse outcomes (HR = 1.43 and 1.34 respectively). In conclusion, to address inequalities in breast cancer survival, improvements in access to healthcare services related to increased travel burden especially for patients of lower socioeconomic status should be considered, more than ever at times of financial crisis and independently of already known modifiable patient characteristics.
Breast cancer Survival Prognosis Healthcare access Healthcare inequalities Obesity Socioeconomic status (SES)
The present study complies with the current laws of the Greece.
Conflict of interest
All authors declare that they have no conflict of interest.
Soerjomataram I, Louwman MWJ, Ribot JG, Roukema JA, Coebergh JWW. An overview of prognostic factors for long-term survivors of breast cancer. Breast Cancer Res Treat. 2008;107(3):309–30.PubMedCrossRefGoogle Scholar
Clarke M, Collins R, Darby S, Davies C, Elphinstone P, Evans E, et al. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;366(9503):2087–106. doi:10.1016/S0140-6736(05)67887-7.PubMedGoogle Scholar
Malamou-Mitsi V, Gogas H, Dafni U, Bourli A, Fillipidis T, Sotiropoulou M, et al. Evaluation of the prognostic and predictive value of p53 and Bcl-2 in breast cancer patients participating in a randomized study with dose-dense sequential adjuvant chemotherapy. Ann Oncol. 2006;17(10):1504–11. doi:10.1093/annonc/mdl147.PubMedCrossRefGoogle Scholar
Dal Maso L, Zucchetto A, Talamini R, Serraino D, Stocco CF, Vercelli M, et al. Effect of obesity and other lifestyle factors on mortality in women with breast cancer. Int J Cancer. 2008;123(9):2188–94.PubMedCrossRefGoogle Scholar
Hellmann SS, Thygesen LC, Tolstrup JS, Gronbaek M. Modifiable risk factors and survival in women diagnosed with primary breast cancer: results from a prospective cohort study. Eur J Cancer Prevent. 2010;19(5):366–73. doi:10.1097/CEJ.0b013e32833b4828.CrossRefGoogle Scholar
Pierce JP, Stefanick ML, Flatt SW, Natarajan L, Sternfeld B, Madlensky L, et al. Greater Survival after breast cancer in physically active women with high vegetable-fruit intake regardless of obesity. J Clin Oncol. 2007;25(17):2345–51. doi:10.1200/jco.2006.08.6819.PubMedCrossRefGoogle Scholar
Parkin DM, Boyd L. Cancers attributable to overweight and obesity in the UK in 2010. Br J Cancer. 2011;105(S2):S34–7.PubMedCrossRefGoogle Scholar
Protani M, Coory M, Martin J. Effect of obesity on survival of women with breast cancer: systematic review and meta-analysis. Breast Cancer Res Treat. 2010;123(3):627–35.PubMedCrossRefGoogle Scholar
Berclaz G, Li S, Price KN, Coates AS, Castiglione-Gertsch M, Rudenstam CM, et al. Body mass index as a prognostic feature in operable breast cancer: the International Breast Cancer Study Group experience. Ann Oncol. 2004;15(6):875–84. doi:10.1093/annonc/mdh222.PubMedCrossRefGoogle Scholar
Bouchardy C, Verkooijen HM, Fioretta G. Social class is an important and independent prognostic factor of breast cancer mortality. Int J Cancer. 2006;119(5):1145–51.PubMedCrossRefGoogle Scholar
Dalton SO, Ross L, Düring M, Carlsen K, Mortensen PB, Lynch J, et al. Influence of socioeconomic factors on survival after breast cancer—a nationwide cohort study of women diagnosed with breast cancer in Denmark 1983–1999. Int J Cancer. 2007;121(11):2524–31.PubMedCrossRefGoogle Scholar
Probst J, Laditka S, Wang J-Y, Johnson A. Effects of residence and race on burden of travel for care: cross sectional analysis of the 2001 US National Household Travel Survey. BMC Health Services Res. 2007;7(1):40.CrossRefGoogle Scholar
Zgibor JC, Gieraltowski LB, Talbott EO, Fabio A, Sharma RK, Karimi H. The association between driving distance and glycemic control in rural areas. J Diabetes Sci Technol. 2011;5(3):494–500.PubMedGoogle Scholar
Scoggins JF, Fedorenko CR, Donahue SMA, Buchwald D, Blough DK, Ramsey SD. Is distance to provider a barrier to care for medicaid patients with breast, colorectal, or lung cancer? J Rural Health. 2011; Article first published online: 31 Mar 2011. doi:10.1111/j.1748-0361.2011.00371.x.
Dejardin O, Remontet L, Bouvier AM, Danzon A, Tretarre B, Delafosse P, et al. Socioeconomic and geographic determinants of survival of patients with digestive cancer in France. Br J Cancer. 2006;95(7):944–9.PubMedCrossRefGoogle Scholar
Crawford SM, Sauerzapf V, Haynes R, Zhao H, Forman D, Jones AP. Social and geographical factors affecting access to treatment of lung cancer. Br J Cancer. 2009;101(6):897–901.PubMedCrossRefGoogle Scholar
Athas WF, Adams-Cameron M, Hunt WC, Amir-Fazli A, Key CR. Travel distance to radiation therapy and receipt of radiotherapy following breast-conserving surgery. J Natl Cancer Inst. 2000;92(3):269–71. doi:10.1093/jnci/92.3.269.PubMedCrossRefGoogle Scholar
Jones AP, Haynes R, Sauerzapf V, Crawford SM, Zhao H, Forman D. Travel time to hospital and treatment for breast, colon, rectum, lung, ovary and prostate cancer. Eur J Cancer. 2008;44(7):992–9.PubMedCrossRefGoogle Scholar
Baird G, Flynn R, Baxter G, Donnelly M, Lawrence J. Travel time and cancer care: an example of the inverse care law? Rural Remote Health. 2008;8(4):1003 (Online). Epub Nov 13, 2008.Google Scholar
Fountzilas G, Skarlos D, Dafni U, Gogas H, Briasoulis E, Pectasides D, et al. Postoperative dose-dense sequential chemotherapy with epirubicin, followed by CMF with or without paclitaxel, in patients with high-risk operable breast cancer: a randomized phase III study conducted by the Hellenic Cooperative Oncology Group. Ann Oncol. 2005;16(11):1762–71. doi:10.1093/annonc/mdi366.PubMedCrossRefGoogle Scholar
Fountzilas G, Dafni U, Gogas H, Linardou H, Kalofonos HP, Briasoulis E, et al. Postoperative dose-dense sequential chemotherapy with epirubicin, paclitaxel and CMF in patients with high-risk breast cancer: safety analysis of the Hellenic Cooperative Oncology Group randomized phase III trial HE 10/00. Ann Oncol. 2008;19(5):853–60. doi:10.1093/annonc/mdm539.PubMedCrossRefGoogle Scholar
Gogas H, Dafni U, Karina M, Papadimitriou C, Batistatou A, Bobos M, et al. Postoperative dose-dense sequential versus concomitant administration of epirubicin and paclitaxel in patients with node-positive breast cancer: 5-year results of the Hellenic Cooperative Oncology Group HE 10/00 phase III Trial. Breast Cancer Res Treat. 2011;2011 Dec 21. [Epub ahead of print] doi:10.1007/s10549-011-1913-4.
Papadimitriou CA, Papakostas P, Timotheadou E, Aravantinos G, Bamias A, Fountzilas G. Adjuvant dose-dense sequential chemotherapy with epirubicin, CMF and Weekly paclitaxel in patients with resected high-risk breast cancer: a Hellenic Cooperative Oncology Group (HeCOG) Study. Cancer Invest. 2008;26(5):491–8. doi:10.1080/07357900701829785.PubMedCrossRefGoogle Scholar
Fountzilas G, Pectasides D, Christodoulou C, Timotheadou E, Economopoulos T, Papakostas P, et al. Adjuvant dose-dense sequential chemotherapy with epirubicin, CMF, and weekly docetaxel is feasible and safe in patients with operable breast cancer. Med Oncol. 2006;23(4):479–88.PubMedCrossRefGoogle Scholar
Celaya M, Rees J, Gibson J, Riddle B, Greenberg E. Travel distance and season of diagnosis affect treatment choices for women with early-stage breast cancer in a predominantly rural population (United States). Cancer Causes Control. 2006;17(6):851–6.PubMedCrossRefGoogle Scholar
Wan Y. Examine the effect of geographic distance on breast cancer patients’ utilization of high volume hospitals [Master of Science Thesis]. Iowa. University of Iowa; 2009. http://ir.uiowa.edu/etd/446.
Wee C, McCarthy E, Davis R, Phillips R. Screening for cervical and breast cancer: is obesity an unrecognized barrier to preventive care? Ann Intern Med. 2000;132(9):697–704.PubMedGoogle Scholar
Charalampopoulou A, Petridou E, Spyridopoulos T, Dessypris N, Oikonomou A, Athanasiadou-Piperopoulou F, et al. An integrated evaluation of socioeconomic and clinical factors in the survival from childhood acute lymphoblastic leukaemia: a study in Greece. Eur J Cancer Prev. 2004;13(5):397–401.PubMedCrossRefGoogle Scholar
Lightfoot TJ, Johnston WT, Simpson J, Smith AG, Ansell P, Crouch S, et al. Survival from childhood acute lymphoblastic leukaemia: the impact of social inequality in the United Kingdom. Eur J Cancer. 2012;48(2):263–9.PubMedGoogle Scholar
Vona-Davis L, Rose DP. The influence of socioeconomic disparities on breast cancer tumor biology and prognosis: a review. J Womens Health (Larchmt). 2009;18(6):883–93. doi:10.1089/jwh.2008.1127.CrossRefGoogle Scholar
Petrelli JM, Calle EE, Rodriguez C, Thun MJ. Body mass index, height, and postmenopausal breast cancer mortality in a prospective cohort of US women. Cancer Causes Control. 2002;13(4):325–32.PubMedCrossRefGoogle Scholar
Hall HI, Coates RJ, Uhler RJ, Brinton LA, Gammon MD, Brogan D, et al. Stage of breast cancer in relation to body mass index and bra cup size. Int J Cancer. 1999;82(1):23–7.PubMedCrossRefGoogle Scholar
McTiernan A, Rajan KB, Tworoger SS, Irwin M, Bernstein L, Baumgartner R, et al. Adiposity and sex hormones in postmenopausal breast cancer survivors. J Clin Oncol. 2003;21(10):1961–6.PubMedCrossRefGoogle Scholar
Maehle B, Tretli S. Pre-morbid body-mass-index in breast cancer: reversed effect on survival in hormone receptor negative patients. Breast Cancer Res Treat. 1996;41(2):123–30.PubMedCrossRefGoogle Scholar
Sparano J, Wang M, Martino S, Jones V, Perez E, Saphner T, et al. editors [S2-1]. Obesity at Diagnosis Is Associated with Inferior Outcomes in Hormone Receptor Positive Breast Cancer. 33rd Annual San Antonio Breast Cancer Symposium; 2010; San Antonio, Texas, USA.Google Scholar
Ademuyiwa FO, Groman A, O’Connor T, Ambrosone C, Watroba N, Edge SB. Impact of body mass index on clinical outcomes in triple-negative breast cancer. Cancer. 2011;117(18):4132–40.PubMedCrossRefGoogle Scholar
Parolin V, Fiorio E, Mercanti A, Riolfi M, Cetto GL, Surmacz E, et al. Impact of BMI on clinical outcome of HER2-positive breast cancer. J Clin Oncol. 2010;28:15s(suppl;abstr 1130).Google Scholar
Gunter MJ, Hoover DR, Yu H, Wassertheil-Smoller S, Rohan TE, Manson JE, et al. Insulin, insulin-like growth factor-i, and risk of breast cancer in postmenopausal women. J Natl Cancer Inst. 2009;101(1):48–60. doi:10.1093/jnci/djn415.PubMedCrossRefGoogle Scholar
Kentikelenis A, Karanikolos M, Papanicolas I, Basu S, McKee M, Stuckler D. Health effects of financial crisis: omens of a Greek tragedy. Lancet. 2011;378(9801):1457–8.PubMedCrossRefGoogle Scholar